PLpro inhibitor 19, identified by its CAS number 2863607-73-0, is a small molecule designed to inhibit the papain-like protease (PLpro) of coronaviruses, including SARS-CoV-2. This compound is part of a broader effort to develop antiviral agents targeting viral proteases, which play crucial roles in the replication and maturation of viruses. The characteristics of PLpro inhibitor 19 include its specific binding affinity to the active site of the PLpro enzyme, which disrupts its function and thereby impedes viral replication. The compound is typically characterized by its molecular structure, which includes specific functional groups that enhance its inhibitory activity and selectivity. Additionally, it may exhibit favorable pharmacokinetic properties, such as good solubility and bioavailability, making it a potential candidate for therapeutic development. Research into PLpro inhibitors like this one is critical for advancing treatment options against viral infections, particularly in the context of emerging viral threats.

PLpro inhibitor 19

2863607-73-0: PLpro inhibitor 19, identified by its CAS number 2863607-73-0, is a small molecule designed to inhibit the papain-like protease (PLpro) of coronaviruses, including SARS-CoV-2. This compound is part of a broader effort to develop antiviral agents targeting viral proteases, which play crucial roles in the replication and maturation of viruses. The characteristics of PLpro inhibitor 19 include its specific binding affinity to the active site of the PLpro enzyme, which disrupts its function and thereby impedes viral replication. The compound is typically characterized by its molecular structure, which includes specific functional groups that enhance its inhibitory activity and selectivity. Additionally, it may exhibit favorable pharmacokinetic properties, such as good solubility and bioavailability, making it a potential candidate for therapeutic development. Research into PLpro inhibitors like this one is critical for advancing treatment options against viral infections, particularly in the context of emerging viral threats.

<p>SARS-CoV-2-IN-106 (compound 19) is a SARS-CoV-2 papain-like protease inhibitor, displaying IC50 values of 0.44 μM for papain-like proteases and 0.18 μM for viral replication.</p>

CAS 2863607-73-0

PLpro inhibitor 19

SARS-CoV-2-IN-106

Ref: TM-T201420